Sofia Smith

a adăugat un sunet Home

2022-12-21 11:18:47

In 2019, owing to the failure to meet the desired endpoints, two big pharma players, Abbvie and Biogen announced their decision to terminate the development of their pipeline anti-tau antibodies for PSP, namely ABBV-8E12 and gosuranemab, respectively.

Progressive Supranuclear Palsy (PSP) Therapies market Size, Share and Industry Trends by 2030

Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031Since John Steele, John Richardson, and Jerzy Olszewski first described PSP in 1964, the neuroscience community has been on the lookout to find a “miracle molecule” or an “elixir” that can cure patients diagnosed with this debilitating disease.With more than 2,000 research studies published...

·3K Views ·0 previzualizare

Conecteaza-te

Limbi

Sofia Smith

Progressive Supranuclear Palsy (PSP) Therapies market Size, Share and Industry Trends by 2030